Yecuris Corporation

Whether you are building innovative gene therapies, targeting NASH, creating the next cure for a liver disease, or testing your small molecule for metabolism or toxicology, you need real data from from real human hepatocytes as early as possible. Thats why for more than a decade, researchers have trusted the FRG platform for their liver studies. Yecuris FRG are chimeric animal models with more than 70% of the liver replaced with human hepatocytes providing researchers with actionable insights into liver-specific questions at the cellular, tissue, and animal level

Chimeric animal engineering,drug discovery and development,stem cell technologies,human health and healing advocates,gene and cell therapy,nash,and infectious disease

Yecuris corporation operates in the Biotechnology research industry.

Yecuris corporation's revenue is 11m - 100m

Yecuris corporation has 11 - 50 employees.